antithrombotics

Abciximab - Apixaban - Bivalirudin - Coumadin - Dabigatran - Deltaparin - Dicoumarol - Edoxaban - Eptifibatide - Fondaparinux - Fraxiparin - Heparin - Hirudin - Idraparinux - LMWH - Reviparin - Rivaroxaban - Tirofiban - UFH - Wafarin - Warfarin - Ximelagatran      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
argatroban
ARGAMI-2, 1998       Argatrobanheparin -
aspirin
ATACS-pilot, 1990   aspirincontrolnegative
VA-pilot   aspirinplacebonegative
VA-main, 1983   aspirinplaceboLow risk of bias suggesting
RISC, 1990   aspirinplaceboLow risk of bias suggesting
ALDUSA-pilot   aspirinplacebonegative
Théroux, 1988   aspirinplaceboLow risk of bias suggesting
Canadian (Aspirin vs PBO), 1985   aspirinplaceboLow risk of bias -
Canadian (Aspirin + sulfinpyrazone), 1985   aspirin + sulfinpyrazoneplaceboLow risk of bias negative
atopaxar
LANCELOT ACS     atopaxarplaceboExploratory -
J-LANCELOT, 2010   atopaxarplaceboExploratory -
bivalirudin
ACUITY (biva alone vs hep+aGP2b3a), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsLow risk of bias suggesting-23%19%
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006    NCTbivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsLow risk of bias negative-6%13%
PROTECT-TIMI 30, 2006      NCTbivalirudineptifibatide + heparinExploratory -
HERO, 1997     bivalirudinheparinLow risk of bias suggesting
BAT (Bittl), 1995     bivalirudinheparinLow risk of bias suggesting
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007         bivalirudinheparin + GP2b3a inhibitorssuggesting-48%19%
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007     bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsnegative11%28%
clopidogrel
CURE (PCI sub study), 2001     clopidogrelplaceboLow risk of bias -
CURE, 2001     clopidogrel + aspirinaspirinLow risk of bias suggesting 38%
CURRENT OASIS 7 (clopidogrel), 2010    NCTclopidogrel high-dose regimenclopidogrel standard-doseLow risk of bias negative 24%-4%
coumadin
ASPECT-2 (coumadin+asp vs asp), 2002     coumadincontrol (on top of aspirin)suggesting135%
ASPECT-2 (coumadin vs aspirin), 2002   coumadinaspirinsuggesting3%
dalteparin
FRISC (long term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias suggesting-15%
FRIC prolonged treatment phase (LWMH vs PBO), 1997     dalteparinplacebo (on top of aspirin)Low risk of bias negative61%
FRISC (short term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias -
FRIC (acute phase LMWH vs UFH), 1997     dalteparinUFH (on top of aspirin)Exploratory negative257%
dipyridamol
Prandoni, 1991   aspirin + dipyridamolplaceboLow risk of bias negative
Efegatran
Klootwijk, 1999     EfegatranheparinExploratory -
enoxaparin
RESCUE    NCTenoxaparinunfractionated heparin -
EVET, 2005     enoxaparintinzaparinsuggesting-50%
ESSENCE, 1997     enoxaparinUFH (on top of aspirin)Low risk of bias suggesting -7%-3%
TIMI 11 B (short term), 1998   enoxaparinUFH (on top of aspirin)Low risk of bias suggesting 52%-17%
SYNERGY, 2005          NCTenoxaparinUFH (on top of aspirin)negative 19%4%
INTERACT, 2006       enoxaparinUFH (on top of aspirin)suggesting -60%-42%
TIMI 11 B (long term), 1998   enoxaparinUFH (on top of aspirin)Low risk of bias negative 90%-4%
fondaparinux
PENTUA, 2004     fondaparinuxenoxaparin -
OASIS 5, 2006      NCTfondaparinuxenoxaparinLow risk of bias -
hirudin
HIT-4, 1999     HirudinheparinLow risk of bias -
TIMI 9B, 1996     HirudinheparinRisk of bias -
GUSTO IIB, 1996     HirudinheparinRisk of bias -
OASIS pilot, 1997     HirudinheparinExploratory -
HELVETICA (Serruys), 1995     HirudinheparinLow risk of bias -
OASIS 2, 1999     HirudinheparinLow risk of bias -
OASIS, 1997   HirudinheparinRisk of bias -
inogatran
TRIM, 1997     InogatranheparinLow risk of bias -
nadroparin
FRAXIS (6days), 1998     nadroparinUFH (on top of aspirin)Low risk of bias negative6%
FRAXIS (14 days), 1998     nadroparinUFH (on top of aspirin)Low risk of bias negative26%
otamixaban
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
prasugrel
TRILOGY ACS (overall population), 2012        NCTprasugrelclopidogrelLow risk of bias negative21%-6%
TRITON-TIMI 38, 2007      NCTprasugrelclopidogrelLow risk of bias suggesting 31%-5%
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
sulfinpyrazone
Canadian (sulfinpyrazone alone), 1985   sulfinpyrazoneplaceboLow risk of bias -
ticagrelor
PLATO, 2009      NCTticagrelorclopidogrelLow risk of bias suggesting3%-22%
DISPERSE-2 (90mg), 2007       ticagrelorclopidogrelLow risk of bias negative-2%37%
ticlopidine
STAI, 1990   ticlopidinecontrolsuggesting
Florida UA   ticlopidineplacebonegative
trapidil
Modena   trapidilplacebosuggesting
triflusal
TIM, 2000     triflusalaspirinLow risk of bias -
Plaza, 1993   triflusalplaceboLow risk of bias suggesting
UFH
Holdright, 1994   UFHcontrol (on top of aspirin)negative-15%
RISC (heparin+aspirin vs ASP), 1990   UFHcontrol (on top of aspirin)negative
Theroux (heparin+ASP vs ASP), 1988   UFHcontrol (on top of aspirin)Low risk of bias suggesting
ATACS (Cohen), 1994   UFH, warfarincontrol (on top of aspirin)negative606%4%
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990     UFH, warfarincontrol (on top of aspirin)negative
Theroux (heparin vs PBO), 1988   UFHplaceboLow risk of bias suggesting-100%
RISC (heparin vs PBO), 1990   UFHplacebonegative
Theroux (heparin+aspirin vs PBO), 1988   UFH + aspirinplaceboLow risk of bias suggesting-100%
RISC (ASP+ heparin vs PBO), 1990   UFH + aspirinplacebosuggesting
Gurfinkel (UFH+aspririn vs aspirin), 1995     UFHplacebo (on top of aspirin)Low risk of bias negative421%
Cohen (ATACS pilot) (heparin vs asp), 1990     UFH, warfarinaspirinnegative
vorapaxar
TRACER, 2011      NCTvorapaxarplacebo (on top standard therapy) Low risk of bias -
warfarin
ATACS (pilot study) (warfarin vs control), 1990     warfarincontrol (on top of aspirin)negative-14%
ATACS, 1994   warfarincontrol (on top of aspirin)negative+Infini%
CARS, 1997     warfarincontrol (on top of aspirin)negative29%
OASIS Pilot (phase 1), 1998     warfarincontrol (on top of aspirin)negative+Infini%
OASIS Pilot (phase 2), 1998     warfarincontrol (on top of aspirin)negative102%
OASIS-2 Warfarin Substudy, 2001     warfarincontrol (on top of aspirin)negative 98%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)negative3%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%
WARIS, 2002     warfarincontrol (on top of aspirin)suggesting 249%
LoWASA, 2004     warfarincontrol (on top of aspirin)negative 104%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative150%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias negative+Infini%
Huyhn, 2001     warfarinplacebo (on top of aspirin)Low risk of bias negative+Infini%
ATACS (pilot study) warfarin vs aspirin, 1990     warfarinaspirinnegative
ximelagatran
ESTEEM, 2003   ximelagatranplaceboExploratory -

acute myocardial infarction

argatroban
ARGAMI-2, 1998       Argatrobanheparin -
bivalirudin
HERO, 1997     bivalirudinheparinLow risk of bias suggesting
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002     coumadincontrol (on top of aspirin)negative 126%-42%
ASPECT, 1994   coumadinplaceboLow risk of bias suggesting 285%-10%
ASPECT-2 (coumadin alone), 2002     coumadinaspirinsuggesting3%-72%
dalteparin
FRAMI, 1997     Dalteparinplacebo -
BIOMACS II, 1999     DalteparinplaceboLow risk of bias -
ASSENT Plus, 2003     DalteparinUFHnegative
enoxaparin
AMI-SK, 2002     EnoxaparinplaceboLow risk of bias -
ASSENT 3, 2001     EnoxaparinUFHsuggesting
HART II, 2001     EnoxaparinUFHnegative
Baird, 2002     EnoxaparinUFHnegative
ENTIRE-TIMI 2, 2002     EnoxaparinUFHsuggesting
ASSENT 3 Plus, 2003     EnoxaparinUFHnegative
fondaparinux
MICHELANGELO OASIS-6, 2006      NCTfondaparinuxplaceboLow risk of bias suggesting-17%
hirudin
HIT-4, 1999     HirudinheparinLow risk of bias -
TIMI 9B, 1996     HirudinheparinRisk of bias -
reviparin
CREATE, 2005     ReviparinplaceboLow risk of bias -
UFH
ISIS-2 Pilot, 1987     UFHno heparinnegative
DUCCS, 1994   UFHno heparinnegative
ECSG, 1992     UFHplaceboLow risk of bias negative
OSIRIS, 1992   UFHplaceboLow risk of bias negative
warfarin
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting3%+Infini%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative 150%-67%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
CHAMP, 2002     warfarincontrol (on top of aspirin)negative